Kura Oncology reported first-quarter 2025 results that reflect a transition from early-stage development to near-term commercial potential driven by ziftomenib (menin inhibitor) in NPM1-mutant AML. The company announced a March 31, 2025 NDA submission for ziftomenib with priority-review consideration, underscoring a pivotal near-term regulatory milestone. Total revenue for Q1 2025 was $14.1 million (Kyowa Kirin collaboration), while R&D and G&A expenses totaled $55.973 million and $22.835 million, respectively, producing a net loss of $57.4 million and an EBITDA of approximately $-64.7 million. The quarterly cash balance ended at $51.3 million, and on a pro forma basis, adjusted cash and investments stood at $703.2 million after the $45 million NDA milestone payment, signaling substantial liquidity to fund ziftomenib through commercialization and to advance the broader pipeline through 2025 and into 2027.